The company has completed the patient enrollment of the P-IV trial evaluating Tepezza vs PBO in a ratio (2:1) in 57 patients with TED associated with a low CAS. After the treatment is complete, proptosis nonresponders may elect to enter an OLE phase during which they will receive 8 Tepezza infusions
The primary efficacy of EPs is the change from baseline @24wk. in proptosis & the trial will also evaluate proptosis responder rate, diplopia responder rate, change in orbital pain, change in muscle volume & GO-QoL questionnaire appearance, and visual functioning subscales. The results are expected in Q2’23
Additionally, the results showed an improvement in debilitating symptoms of TED in patients with inflammatory disease
Ref: Horizon | Image: Horizon
